Regeneron Pharmaceuticals Inc. – best known for its antibody drug development platform and commercial success with Eylea (aflibercept) – is pivoting increasingly toward oncology. The company has one cancer drug on the market, the PD-1 inhibitor Libtayo (cemiplimab) in partnership with Sanofi, but behind it are a maturing pipeline of bispecific antibodies that Regeneron hopes will catapult the company into a serious oncology player.
Regeneron Wades Deeper Into Oncology With Ambitions To Be A Force In The Space
Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.
More from Anticancer
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.